Novartis

Researchers from the Broad Institute and Novartis used RNA interference to generate catalogs of genes that cancer cells rely on to grow and survive.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

A US Food and Drug Administration panel recommends that the agency approve a gene therapy for pediatric leukemia, the New York Times reports.

The initial FDA approval of Thermo Fisher's NGS panel test for personalizing cancer treatment may allow rapid expansion to new indications.

The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments. 

The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.

The agency approved Novartis' Rydapt for AML patients with FLT3 mutations, who will be identified by Invivoscribe's LeukoStrat CDx.

The business was acquired by two private investment groups and a management group led by Prometheus Laboratories' former CEO.

Under the deal, Novartis will access patients who have used Perthera's Precision Cancer Analysis service, which facilitates molecular profiling of cancers.

Novartis will retain Genoptix's biopharma business, which will be renamed Navigate BioPharma Services.

Pages

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.